NYSE:NVO - Novo Nordisk Stock Price, Price Target & More

$47.10 -0.13 (-0.28 %)
(As of 04/23/2018 11:31 AM ET)
Previous Close$47.23
Today's Range$46.82 - $47.11
52-Week Range$36.39 - $58.37
Volume599,719 shs
Average Volume1.43 million shs
Market Capitalization$115.41 billion
P/E Ratio20.05
Dividend Yield1.92%
Beta0.67

About Novo Nordisk (NYSE:NVO)

Novo Nordisk logoNovo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888

Debt

Debt-to-Equity RatioN/A
Current Ratio1.28%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E Ratio20.05
Forward P/E Ratio17.64
P/E Growth2.42

Sales & Book Value

Annual Sales$16.96 billion
Price / Sales6.79
Cash Flow$2.5598 per share
Price / Cash18.40
Book Value$3.10 per share
Price / Book15.19

Profitability

EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins34.09%
Return on Equity82.72%
Return on Assets39.16%

Miscellaneous

Employees42,076
Outstanding Shares2,443,530,000

How to Become a New Pot Stock Millionaire

Novo Nordisk (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk's stock symbol?

Novo Nordisk trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk pay dividends? What is the dividend yield for Novo Nordisk?

Novo Nordisk announced a special dividend on Monday, February 5th. Stockholders of record on Monday, March 26th will be given a dividend of $0.8117 per share on Tuesday, April 3rd. This represents a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, March 23rd. View Novo Nordisk's Dividend History.

How will Novo Nordisk's stock buyback program work?

Novo Nordisk announced that its Board of Directors has initiated a stock repurchase program on Friday, February 2nd 2018, which permits the company to buyback shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board believes its stock is undervalued.

How were Novo Nordisk's earnings last quarter?

Novo Nordisk (NYSE:NVO) announced its quarterly earnings results on Thursday, February, 1st. The company reported $0.53 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.57 by $0.04. The firm earned $4.43 billion during the quarter, compared to analyst estimates of $4.27 billion. Novo Nordisk had a return on equity of 82.72% and a net margin of 34.09%. View Novo Nordisk's Earnings History.

When is Novo Nordisk's next earnings date?

Novo Nordisk is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Novo Nordisk.

Are investors shorting Novo Nordisk?

Novo Nordisk saw a decline in short interest in March. As of March 29th, there was short interest totalling 1,255,045 shares, a decline of 42.5% from the March 15th total of 2,182,514 shares. Based on an average trading volume of 1,221,682 shares, the short-interest ratio is currently 1.0 days. Currently, 0.1% of the company's stock are sold short.

Who are some of Novo Nordisk's key competitors?

Who are Novo Nordisk's key executives?

Novo Nordisk's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
  • Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)

Has Novo Nordisk been receiving favorable news coverage?

Media stories about NVO stock have been trending somewhat negative on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novo Nordisk earned a news sentiment score of -0.02 on Accern's scale. They also gave media coverage about the company an impact score of 46.14 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Novo Nordisk?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk's stock price today?

One share of NVO stock can currently be purchased for approximately $46.97.

How big of a company is Novo Nordisk?

Novo Nordisk has a market capitalization of $115.41 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk employs 42,076 workers across the globe.

How can I contact Novo Nordisk?

Novo Nordisk's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk (NVO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  517
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novo Nordisk (NYSE:NVO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Novo Nordisk in the last 12 months. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.602.602.331.89
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Novo Nordisk (NYSE:NVO) Consensus Price Target History

Price Target History for Novo Nordisk (NYSE:NVO)

Novo Nordisk (NYSE:NVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018Deutsche BankReiterated RatingBuyLowView Rating Details
12/29/2017JPMorgan ChaseUpgradeUnderweight -> NeutralLowView Rating Details
12/6/2017Bank of AmericaUpgradeNeutral -> BuyMediumView Rating Details
12/1/2017Morgan StanleyUpgradeEqual Weight -> OverweightMediumView Rating Details
9/25/2017BNP ParibasDowngradeOutperform -> NeutralHighView Rating Details
3/7/2017BarclaysInitiated CoverageUnderweightN/AView Rating Details
12/20/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
12/6/2016UBSUpgradeSell -> BuyN/AView Rating Details
12/1/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
10/31/2016DNB MarketsDowngradeBuy -> HoldN/AView Rating Details
10/31/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
9/23/2016Piper JaffrayInitiated CoverageNeutralN/AView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformN/AView Rating Details
6/28/2016Goldman SachsDowngradeConviction-Buy -> BuyN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Novo Nordisk (NYSE:NVO) Earnings History and Estimates Chart

Earnings by Quarter for Novo Nordisk (NYSE:NVO)

Novo Nordisk (NYSE:NVO) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.69$0.69$0.69

Novo Nordisk (NYSE NVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
2/1/2018Q4 2017$0.57$0.53$4.2681 billion$4.4292 billionViewN/AView Earnings Details
11/1/2017Q3 2017$0.58$0.62$4.3007 billion$4.2033 billionViewN/AView Earnings Details
8/10/2017Q2 2017$0.56$0.59$4.2882 billion$4.2342 billionViewN/AView Earnings Details
5/3/2017Q1 2017$0.53$0.58$4.1122 billion$4.0774 billionViewN/AView Earnings Details
2/2/2017Q4 2016$0.52$0.50$4.3288 billion$4.29 billionViewN/AView Earnings Details
10/28/2016Q3 2016$0.56$0.58$4.2217 billion$4.1273 billionViewN/AView Earnings Details
8/5/2016Q2 2016$0.58$0.60$4.2092 billion$4.1688 billionViewN/AView Earnings Details
4/29/2016Q1$0.53$0.55$4.0676 billion$4.0232 billionViewListenView Earnings Details
2/3/2016Q4 2015$0.48$0.47$4.1561 billion$4.2390 billionViewN/AView Earnings Details
10/29/2015Q3$0.47$0.49$4.0256 billion$3.9947 billionViewN/AView Earnings Details
8/6/2015Q2 2015$0.48$3.9735 billion$4.0101 billionViewN/AView Earnings Details
4/30/2015Q1$0.39$0.45$25.1254 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.6673 billion$24.5850 billionViewN/AView Earnings Details
10/30/2014Q3 2014$0.42$3.8032 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.8569 billion$21.6290 billionViewN/AView Earnings Details
5/1/2014Q1$0.44$0.45$20.8333 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42$3.9710 billionViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.0426 billion$20.5110 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.0879 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.7317 billion$19.9830 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.8289 billion$20.9620 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
8/9/2012Q2 2012$0.32ViewN/AView Earnings Details
4/27/2012Q1 2012$0.30ViewN/AView Earnings Details
2/2/2012Q4 2011$0.26$0.30ViewN/AView Earnings Details
10/27/2011Q3 2011$0.27$0.28ViewN/AView Earnings Details
8/4/2011Q2 2011$0.29$0.28ViewN/AView Earnings Details
2/2/2011Q4 2010$0.27$0.25ViewN/AView Earnings Details
10/27/2010Q3 2010$0.23ViewN/AView Earnings Details
8/19/2010Q2 2010$0.19$0.21ViewN/AView Earnings Details
4/30/2010Q1 2009$0.16ViewN/AView Earnings Details
2/2/2010Q4 2009$0.16ViewN/AView Earnings Details
10/29/2009Q3 2009$0.18ViewN/AView Earnings Details
1/29/2009Q4 2008$0.13ViewN/AView Earnings Details
10/30/2008Q3 2008$0.17ViewN/AView Earnings Details
4/30/2008Q1 2008$0.14ViewN/AView Earnings Details
1/31/2008Q4 2007$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novo Nordisk (NYSE:NVO) Dividend Information

Novo Nordisk pays an annual dividend of $0.91 per share, with a dividend yield of 1.93%. NVO's most recent special dividend payment was Tuesday, April 3. Novo Nordisk pays out 38.89% of its earnings out as a dividend.
Most Recent Dividend:4/3/2018
Annual Dividend:$0.91
Dividend Yield:1.93%
Dividend Growth:10.40% (3 Year Average)
Payout Ratio:38.89% (Trailing 12 Months of Earnings)
34.08% (Based on This Year's Estimates)
32.16% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novo Nordisk (NYSE:NVO)

Novo Nordisk (NYSE:NVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2018special$0.81170.96%3/23/20183/26/20184/3/2018
8/9/2017annual$0.33601.07%8/18/20178/21/20178/29/2017
2/7/2017annual$0.66341.99%3/23/20173/27/20174/4/2017
8/8/2016$0.32608/11/20168/15/20168/23/2016
2/16/2016Annual$0.70403/18/20163/22/20163/30/2016
3/17/2014annual$0.83901.83%3/21/20143/25/20144/2/2014
2/27/2013annual$3.18381.81%3/21/20133/25/20134/2/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novo Nordisk (NYSE NVO) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 6.69%
Insider Trading History for Novo Nordisk (NYSE:NVO)
Insider Trading History for Novo Nordisk (NYSE:NVO)

Novo Nordisk (NYSE NVO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2017Eric S SprottInsiderBuy50,000$8.34$417,000.00
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.2802$31,876.98
(Data available from 1/1/2013 forward)

Headlines

Novo Nordisk (NYSE NVO) News Headlines

Source:
DateHeadline
MannKind: Experts In Pulling Numbers From OrificesMannKind: Experts In Pulling Numbers From Orifices
seekingalpha.com - April 23 at 8:38 AM
Xultophy® approved in Canada for the treatment of adults with type 2 diabetesXultophy® approved in Canada for the treatment of adults with type 2 diabetes
finance.yahoo.com - April 18 at 5:16 PM
Novo Nordisk (NVO) Sees Large Decline in Short InterestNovo Nordisk (NVO) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 18 at 2:16 AM
$0.69 Earnings Per Share Expected for Novo Nordisk (NVO) This Quarter$0.69 Earnings Per Share Expected for Novo Nordisk (NVO) This Quarter
www.americanbankingnews.com - April 16 at 3:24 AM
Equities Analysts Offer Predictions for Novo Nordisks Q1 2018 Earnings (NVO)Equities Analysts Offer Predictions for Novo Nordisk's Q1 2018 Earnings (NVO)
www.americanbankingnews.com - April 16 at 1:19 AM
Novo Nordisk (NVO) Stock Rating Lowered by BidaskClubNovo Nordisk (NVO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM
Novo-Nordisk Breaks Below 200-Day Moving Average - Notable for NVONovo-Nordisk Breaks Below 200-Day Moving Average - Notable for NVO
www.nasdaq.com - April 13 at 5:04 PM
Novo Nordisk (NVO) Stock Rating Lowered by Zacks Investment ResearchNovo Nordisk (NVO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:33 PM
Tessa Therapeutics announces new Board Member and increase of recent funding roundTessa Therapeutics announces new Board Member and increase of recent funding round
www.prnewswire.com - April 11 at 7:28 PM
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in CanadaNovo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
finance.yahoo.com - April 11 at 9:17 AM
Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in QuebecNovo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec
finance.yahoo.com - April 11 at 9:17 AM
Novo Nordisk Stock Performance in 1Q18Novo Nordisk Stock Performance in 1Q18
finance.yahoo.com - April 10 at 5:02 PM
Novo Nordisk (NVO) Given Average Rating of "Hold" by AnalystsNovo Nordisk (NVO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 8 at 7:33 AM
Novo Nordisk (NVO) Upgraded by Zacks Investment Research to "Buy"Novo Nordisk (NVO) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 7 at 4:58 PM
Novo Nordisk Obtains Licence for Sickle Cell Disease ProgramNovo Nordisk Obtains Licence for Sickle Cell Disease Program
www.zacks.com - April 6 at 5:12 PM
Novo Nordisk buys blood drug licence to boost anaemic biopharma businessNovo Nordisk buys blood drug licence to boost anaemic biopharma business
finance.yahoo.com - April 5 at 10:54 AM
Status regarding Novo Nordisks holding of its own shares (31 March 2018)Status regarding Novo Nordisk's holding of its own shares (31 March 2018)
finance.yahoo.com - April 3 at 8:59 AM
Novo Nordisk (NVO) Earns Buy Rating from Deutsche BankNovo Nordisk (NVO) Earns Buy Rating from Deutsche Bank
www.americanbankingnews.com - March 30 at 12:34 PM
Novo Nordisk A/S (NVO) Downgraded by Zacks Investment ResearchNovo Nordisk A/S (NVO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:51 PM
These 12 Drugs Launching In 2018 Are Headed For Blockbuster StatusThese 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
finance.yahoo.com - March 23 at 5:09 PM
Drugmaker Novo Nordisk looks to former oil boss to energise M&ADrugmaker Novo Nordisk looks to former oil boss to energise M&A
finance.yahoo.com - March 22 at 9:03 AM
Form 6-K NOVO NORDISK AS For: Mar 19 - StreetInsider.comForm 6-K NOVO NORDISK AS For: Mar 19 - StreetInsider.com
www.streetinsider.com - March 20 at 4:50 PM
Zacks Investment Research Lowers Novo Nordisk A/S (NVO) to HoldZacks Investment Research Lowers Novo Nordisk A/S (NVO) to Hold
www.americanbankingnews.com - March 20 at 12:10 PM
Novo Nordisk A/S (NVO) Given Consensus Rating of "Hold" by BrokeragesNovo Nordisk A/S (NVO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 14 at 3:04 PM
Novartis’s Innovative Medicines Business in 4Q17Novartis’s Innovative Medicines Business in 4Q17
finance.yahoo.com - March 14 at 9:26 AM
Global Clinical Trials Market Opportunities 2018: Sanofi Aventis A.S., Novo Nordisk A/S, Roche Group.Global Clinical Trials Market Opportunities 2018: Sanofi Aventis A.S., Novo Nordisk A/S, Roche Group.
www.marketwatch.com - March 13 at 6:52 PM
How AstraZeneca’s Other Products Portfolio Performed in 4Q17How AstraZeneca’s Other Products Portfolio Performed in 4Q17
finance.yahoo.com - March 13 at 6:52 PM
Form 6-K NOVO NORDISK AS For: Mar 12 - StreetInsider.comForm 6-K NOVO NORDISK AS For: Mar 12 - StreetInsider.com
www.streetinsider.com - March 12 at 12:08 PM
Novo Nordisk: Pick Up This Diabetes Leader In 2018 - Seeking Alpha - Seeking AlphaNovo Nordisk: Pick Up This Diabetes Leader In 2018 - Seeking Alpha - Seeking Alpha
seekingalpha.com - March 8 at 9:00 AM
Renaissance Technologies LLC Acquires 1,369,900 Shares of Novo Nordisk A/S (NVO)Renaissance Technologies LLC Acquires 1,369,900 Shares of Novo Nordisk A/S (NVO)
www.americanbankingnews.com - March 6 at 2:50 PM
Novo Nordisk A/S (NVO) Shares Sold by Scotia Capital Inc.Novo Nordisk A/S (NVO) Shares Sold by Scotia Capital Inc.
www.americanbankingnews.com - March 6 at 2:16 PM
Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018
finance.yahoo.com - March 5 at 5:29 PM
Alexion Pharmaceuticals: Strensiq and Kanuma in 2017Alexion Pharmaceuticals: Strensiq and Kanuma in 2017
finance.yahoo.com - March 5 at 5:29 PM
GLP-1 Drug Class May Continue to Drive Growth for Novo NordiskGLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
finance.yahoo.com - March 5 at 8:52 AM
OZEMPIC® now available for Canadians with type 2 diabetesOZEMPIC® now available for Canadians with type 2 diabetes
finance.yahoo.com - March 5 at 8:52 AM
Bank of New York Mellon Corp Has $70.14 Million Stake in Novo Nordisk A/S (NVO)Bank of New York Mellon Corp Has $70.14 Million Stake in Novo Nordisk A/S (NVO)
www.americanbankingnews.com - March 5 at 4:54 AM
Novo Nordisk A/S (NVO) Shares Bought by Assetmark Inc.Novo Nordisk A/S (NVO) Shares Bought by Assetmark Inc.
www.americanbankingnews.com - March 5 at 4:42 AM
Sei Investments Co. Has $4.99 Million Position in Novo Nordisk A/S (NVO)Sei Investments Co. Has $4.99 Million Position in Novo Nordisk A/S (NVO)
www.americanbankingnews.com - March 4 at 8:30 AM
Novo Nordisk A/S (NVO) Position Lifted by Suntrust Banks Inc.Novo Nordisk A/S (NVO) Position Lifted by Suntrust Banks Inc.
www.americanbankingnews.com - March 3 at 9:56 AM
Novo Nordisk A/S (NVO) Shares Sold by Brown Advisory Inc.Novo Nordisk A/S (NVO) Shares Sold by Brown Advisory Inc.
www.americanbankingnews.com - March 3 at 4:56 AM
[$$] Novo to invest $165m in first ‘superbug’ venture fund[$$] Novo to invest $165m in first ‘superbug’ venture fund
finance.yahoo.com - March 2 at 8:48 AM
Performance of Sanofi’s Business Segments in 4Q17Performance of Sanofi’s Business Segments in 4Q17
finance.yahoo.com - March 1 at 5:24 PM
Stock Traders Buy High Volume of Call Options on Novo Nordisk A/S (NVO)Stock Traders Buy High Volume of Call Options on Novo Nordisk A/S (NVO)
www.americanbankingnews.com - March 1 at 7:24 AM
Novo Nordisk A/S (NVO) Shares Bought by BlackRock Inc.Novo Nordisk A/S (NVO) Shares Bought by BlackRock Inc.
www.americanbankingnews.com - March 1 at 5:08 AM
Novo Nordisk A/S (NVO) Position Increased by Eagle Global Advisors LLCNovo Nordisk A/S (NVO) Position Increased by Eagle Global Advisors LLC
www.americanbankingnews.com - February 28 at 2:26 PM
FDx Advisors Inc. Has $1.02 Million Stake in Novo Nordisk A/S (NVO)FDx Advisors Inc. Has $1.02 Million Stake in Novo Nordisk A/S (NVO)
www.americanbankingnews.com - February 28 at 10:52 AM
Novo Holdings launches $165 million superbug drug venture fundNovo Holdings launches $165 million 'superbug' drug venture fund
finance.yahoo.com - February 28 at 8:48 AM
Novo Nordisk A/S (NVO) Shares Bought by Van Hulzen Asset Management LLCNovo Nordisk A/S (NVO) Shares Bought by Van Hulzen Asset Management LLC
www.americanbankingnews.com - February 27 at 2:17 PM
Princeton Capital Management LLC Buys Shares of 52,155 Novo Nordisk A/S (NVO)Princeton Capital Management LLC Buys Shares of 52,155 Novo Nordisk A/S (NVO)
www.americanbankingnews.com - February 27 at 8:26 AM
Liberty Mutual Group Asset Management Inc. Acquires 24,100 Shares of Novo Nordisk A/S (NVO)Liberty Mutual Group Asset Management Inc. Acquires 24,100 Shares of Novo Nordisk A/S (NVO)
www.americanbankingnews.com - February 27 at 7:30 AM

SEC Filings

Novo Nordisk (NYSE:NVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novo Nordisk (NYSE:NVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novo Nordisk (NYSE NVO) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.